Kazia Therapeutics Limited

NasdaqCM KZIA

Kazia Therapeutics Limited Return on Capital Employed (ROCE) for the year ending June 30, 2024

Kazia Therapeutics Limited Return on Capital Employed (ROCE) is NA for the year ending June 30, 2024. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Kazia Therapeutics Limited Return on Capital Employed (ROCE) for the year ending June 30, 2023 was -117.67%, a -40.34% change year over year.
Kazia Therapeutics Limited Return on Capital Employed (ROCE) for the year ending June 30, 2022 was -83.85%, a -554.19% change year over year.
Kazia Therapeutics Limited Return on Capital Employed (ROCE) for the year ending June 30, 2021 was -12.82%.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

NasdaqCM: KZIA

Kazia Therapeutics Limited

CEO	Dr. John Edwin Friend II, M.D.
IPO Date	Jan. 6, 1999
Location	Australia
Headquarters	Three International Towers
Employees	9
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Key trends

Past 5 years